IL6 has dual effects on inflammation; it plays an anti‐inflammatory role at a low dose during the initial stage of injury, whereas it acts as a proinflammatory cytokine at a high dose.[24] The level of IL6 increases with the progression of NAFLD, and IL6 content has been shown to be associated with the severity of NAFLD.[25, 26] IL6 inhibition alleviates NAFLD progression.[27] In our study, the macrophages secreted increased level of IL6. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.